Previous close | 132.61 |
Open | 132.93 |
Bid | 129.91 x 900 |
Ask | 133.53 x 1200 |
Day's range | 131.60 - 133.90 |
52-week range | 102.00 - 149.25 |
Volume | |
Avg. volume | 1,553,818 |
Market cap | 27.067B |
Beta (5Y monthly) | 1.01 |
PE ratio (TTM) | 27.05 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.96 (0.72%) |
Ex-dividend date | 27 Mar 2024 |
1y target est | N/A |
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the ROSA® Shoulder System for robotic-assisted shoulder replacement surgery. ROSA Shoulder is the world's first robotic surgery system for shoulder replacement, and the fourth application for the Company's comprehensive ROSA® Robotics portfolio, which includes the ROSA® Knee System for total knee arthroplasty and ROSA® Hip System for to
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2024. The cash dividend of $0.24 per share is payable on or about April 30, 2024 to stockholders of record as of the close of business on March 29, 2024.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, signed the Global Health Equity Network's (GHEN) Zero Health Gaps Pledge, a commitment from CEOs across industries and regions for their organizations to embed health equity in core strategies, operations and investments. Zimmer Biomet's Health Equity division, established in 2023, has made meaningful strides on core areas of the 10-point pledge, including understanding the drivers of disparity in orthopaedic c